Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Viatris Inc (MYL) is a leading drug manufacturers-specialty & generic business based in the US. It opened the day at USD$N/A after a previous close of USD$N/A. During the day the price has varied from a low of USD$N/A to a high of USD$N/A. The latest price was USD$N/A (25 minute delay). Viatris is listed on the NASDAQ and employs 35,000 staff. All prices are listed in US Dollars.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|52-week range||$0.08 - $16.10|
|50-day moving average||$16.42|
|200-day moving average||$16.12|
|Wall St. target price||$21.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.52|
Valuing Viatris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Viatris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Viatris's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Viatris shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Viatris's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Viatris's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Viatris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.5 billion.
The EBITDA is a measure of a Viatris's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11.5 billion|
|Operating margin TTM||15.72%|
|Gross profit TTM||$4.6 billion|
|Return on assets TTM||3.63%|
|Return on equity TTM||0%|
|Market capitalisation||$8.6 billion|
TTM: trailing 12 months
There are currently 47.1 million Viatris shares held short by investors – that's known as Viatris's "short interest". This figure is 1.4% up from 46.5 million last month.
There are a few different ways that this level of interest in shorting Viatris shares can be evaluated.
Viatris's "short interest ratio" (SIR) is the quantity of Viatris shares currently shorted divided by the average quantity of Viatris shares traded daily (recently around 4.2 million). Viatris's SIR currently stands at 11.15. In other words for every 100,000 Viatris shares traded daily on the market, roughly 11150 shares are currently held short.
However Viatris's short interest can also be evaluated against the total number of Viatris shares, or, against the total number of tradable Viatris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viatris's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Viatris shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Viatris shares, roughly 111 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Viatris.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Viatris.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 37.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Viatris's overall score of 37.23 (as at 12/31/2018) is pretty weak – landing it in it in the 78th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Viatris is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.95/100
Viatris's environmental score of 1.95 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 20.21/100
Viatris's social score of 20.21 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Viatris is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.07/100
Viatris's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Viatris is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Viatris scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Viatris has a damaged public profile.
We're not expecting Viatris to pay a dividend over the next 12 months.
Viatris's shares were split on a 3:2 basis on 8 October 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Viatris shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Viatris shares which in turn could have impacted Viatris's share price.
Over the last 12 months, Viatris's shares have ranged in value from as little as $0.077 up to $16.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viatris's is 1.4656. This would suggest that Viatris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mylan N. V. , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health.
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re from South Africa.
Steps to owning and managing Bucket Studio shares from South Africa.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Steps to owning and managing Evergrande shares from South Africa.
This guide will show you step-by-step instructions on how to buy the Bitcoin Gold (BTG) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the SOLVE (SOLVE) token as well as a list of exchanges you can trade it on.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.